Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice

Applied Microbiology and Biotechnology

Volumn 97, Issue 24, 2013, Pages 10445-10452

  Zhao, Hui ^a   Li, Hao Yang ^a,b   Han, Jian Feng ^a   Deng, Yong Qiang ^a   Li, Yue Xiang ^a   Zhu, Shun Ya ^a   He, Ya Ling ^b   Qin, E De ^a,c   Chen, Rong ^b   Qin, Cheng Feng ^a,c  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Coxsackievirus A16; Saccharomyces cerevisiae; Vaccine; Virus like particles

Indexed keywords

ASIA PACIFIC REGION; COXSACKIEVIRUS A16; CYTOKINE PROFILING; DOSE-DEPENDENT MANNER; PASSIVE IMMUNIZATION; PROTECTIVE IMMUNITIES; PROTEIN COMPOSITION; VIRUS-LIKE PARTICLES;

IMMUNIZATION; MAMMALS; VACCINES; VIRUSES;

YEAST;

3CD PROTEIN; CAPSID PROTEIN; FUNGUS ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; NEUTRALIZING ANTIBODY; P1 PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

CHILD HEALTH; DOSE-RESPONSE RELATIONSHIP; IMMUNITY; IMMUNIZATION; INFANT MORTALITY; MORBIDITY; MORPHOLOGY; PUBLIC HEALTH; RODENT; VACCINE; VIRUS; YEAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; COXSACKIE VIRUS A; COXSACKIE VIRUS A16; CYTOPLASM; DRUG EFFICACY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SACCHAROMYCES CEREVISIAE; SUCROSE GRADIENT; ULTRACENTRIFUGATION; VERO CELL; VIRUS ASSEMBLY; VIRUS LIKE AGENT; WESTERN BLOTTING; YEAST;

PACIFIC OCEAN; PACIFIC RIM;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS, DNA; VACCINATION; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84892179283     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-013-5257-3     Document Type: Article

References (37)

1. Babu JP, Pattnaik P, Gupta N, Shrivastava A, Khan M, Rao P V L (2008) Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26:4655-4663
2. Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP (2010) IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 26:445-458
3. Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z (2013) Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 31:2215-2221
4. Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE (2003) Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9:78-85
5. Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM (1999) Comparison of enterovirus 71 and Coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18:1092-1096
6. Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, Su IJ, Chong PC, Hsieh SM (2013) A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31:2471-2476
7. Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, Wang JR, Hsieh SY, Su IJ, Liu CC (2012) Immunological and biochemical characterization of Coxsackie virus A16 viral particles. PLoS One 7:e49973
8. Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, Tasi HP, Hsiao KN, Liu SJ, Sia C, Wu SC, Lee MS, Hsiao CH, Wang JR, Chow YH, Chong P (2012) Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012:831282
9. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855-1862
10. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C (2007) Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol 178:2361-2369
11. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan enterovirus epidemic working group. N Engl J Med 341:929-935
12. Ho Y, Lin PH, Liu CY, Lee SP, Chao YC (2004) Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 318:833-838
13. Hu YC, Hsu JT, Huang JH, Ho MS, Ho YC (2003) Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 25:919-925
14. Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31:58-83
15. Li SH, Li XF, Zhao H, Jiang T, Deng YQ, Yu XD, Zhu QY, Qin ED, Qin CF (2011) Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus. Immunol Lett 138:156-160
16. Li HY, Han JF, Qin CF, Chen R (2013) Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31(32):3281-3287
17. Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ (2013) Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 9 (8)
18. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY (2003) Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9:291-293
19. Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL (2012) Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30:1305-1312
20. Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z (2012) Avirus-like particle vaccine for Coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30:6642-6648
21. Luo L, Li Y, Cannon PM, Kim S, Kang CY (1992) Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virusneutralizing antibodies. Proc Natl Acad Sci USA 89:10527-10531
22. Mao LX, Wu B, Bao WX, Han FA, Xu L, Ge QJ, Yang J, Yuan ZH, Miao CH, Huang XX, Zhang C, Xu H (2010) Epidemiologyofhand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. J Clin Virol 49:100-104
23. Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J (2012) A neonatal mouse model of Coxsackievirus A16 for vaccine evaluation. J Virol 86:11967-11976
24. Ni H, Yi B, Yin J, Fang T, He T, Du Y, Wang J, Zhang H, Xie L, Ding Y, Gu W, Zhang S, Han Y, Dong H, Su T, Xu G, Cao G (2012) Epidemiological and etiological characteristics of hand, foot, and mouth disease in Ningbo, China, 2008-2011. J Clin Virol 54:342-348
25. Nicklin MJ, Krausslich HG, Toyoda H, Dunn JJ, Wimmer E (1987) Poliovirus polypeptide precursors: expression in vitro and processing byexogenous 3Cand 2Aproteinases. Proc Natl Acad Sci USA 84:4002-4006
26. Qiaoyun F, Xiongfei J, Lihuan L, Angao X (2013) Epidemiology and etiological characteristics of hand, foot and mouth disease in Huizhou City between 2008 and 2011. Arch Virol 158:895-899
27. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9:1149-1176
28. Secrest AM, Shah KN (2013) Picture ofthe month. Hand-foot-and-mouth disease. JAMA Pediatr 167:387-388
29. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778-790
30. Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, How OM, Cardosa MJ, McMinn PC (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13:1733-1741
31. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278
32. Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM (2004) Fatal Coxsackievirus A16 infection. Pediatr Infect Dis J 23:275-276
33. Wright HT Jr, Landing BH, Lennette EH, Mc AR (1963) Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med 268:1041-1044
34. Wuorimaa T, Dagan R, Vakevainen M, Bailleux F, Haikala R, Yaich M, Eskola J, Kayhty H (2001) Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 184:1211-1215
35. Xu W, Liu CF, Yan L, Li JJ, Wang LJ, Qi Y, Cheng RB, Xiong XY (2012) Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 9:8
36. Zhao K, Han X, Wang G, Hu W, Zhang W, Yu XF (2011) Circulating Coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis 17:1537-1540
37. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024-2032